1 / 6

Summary of PK studies thru 10/1/04*

Summary of PK studies thru 10/1/04*. * Samples analyzed thru 5/30/04. Immunosuppressant doses and Cmin after 2-4 weeks of rx. 350. 300. Wk 2. Wk 12. Wk 28. Yr 1. Yr 2. 250. 200. 150. CsA mg/dose. 100. 50. 0. NVP. EFV. 1 PI. 2 PI. kaletra. NNRTI. NNRTI +. +PI. kaletra.

gattis
Télécharger la présentation

Summary of PK studies thru 10/1/04*

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Summary of PK studies thru 10/1/04* * Samples analyzed thru 5/30/04

  2. Immunosuppressant doses and Cmin after 2-4 weeks of rx

  3. 350 300 Wk 2 Wk 12 Wk 28 Yr 1 Yr 2 250 200 150 CsA mg/dose 100 50 0 NVP EFV 1 PI 2 PI kaletra NNRTI NNRTI + +PI kaletra CsA Dosing by ARV and week

  4. 300000 250000 200000 150000 LPV ng*h/mL 100000 50000 0 LPV LPV + NNRTI 7000 6000 5000 4000 RTV ng*h/mL 3000 2000 1000 0 RTV RTV + NNRTI efficacy pretx W2 W12 W28 Y1 Y2 Kaletra AUC by week

  5. 40000 35000 30000 25000 AUC ng*h/mL 20000 15000 10000 5000 0 NFV efficacy pretx NFV+NNRTI W2 W12 W28 Y1 60 M8 50 NFV 40 AUC mcg*h/mL 30 20 10 0 pretx 2 12 28 yr 1 yr 2 time NFV AUC by week M8/NFV AUC by week

  6. 100000 NVP AUC ng*h/mL efficacy pretx Wk 2 80000 Wk 12 Wk 28 Yr 1 Yr 2 60000 40000 NVP+ PI NVP 120000 20000 100000 80000 0 EFV AUC ng*h/mL 60000 40000 20000 0 EFV EFV + PI NNRTI AUC by week

More Related